Search Results for: prohost portfolio

The NEW Prohost Portfolio for 2019

The NEW Prohost Portfolio for 2019

The NEW Prohost Portfolio Small Important Changes We are making some very small but important changes in our portfolio. Each table represents a sector among the various technological divisions that create more effective products currently being used, or intended to be used, in the management of various illnesses...
The Prohost Portfolio: Updating the Stock Targets

The Prohost Portfolio: Updating the Stock Targets

Prohost Letter #419 RE-­EVALUATION ONLY - The Prohost Portfolio comprises biotechnology and biopharmaceutical companies, that we believe have solid scientific fundamentals and dedicated managements. All the firms in the portfolio, except a few, have proprietary technologies, which enable the firms’ scientists to design in house safer and more effective new molecular entity therapeutic molecules . . . This content is for paid subscribers. Please click here …
AstraZeneca: Excellent collaborations. Moderna Therapeutics: Turning public. Will Prohost add it to its Portfolio as promised?

AstraZeneca: Excellent collaborations. Moderna Therapeutics: Turning public. Will Prohost add it to its Portfolio as promised?

In the NEWS AstraZeneca (AZN) announced a collaboration with Cancer Research UK to launch a center of excellence in genetic screening, cancer modelling and big data processing aimed at accelerating the discovery of new cancer medicines. During the announcement of the news, Mene Pangalos, the firm’s Executive Vice President, Innovative Medicines & Early Development, said, the best science doesn’t happen in isolation, which is why AstraZeneca …
Novartis’ Revolution: A new dimension and  Prohost expectations

Novartis’ Revolution: A new dimension and Prohost expectations

The market is outperforming today. There is important news today about Novartis; part of which we are posting now. There is still more news related to this same company as well as other biotech and biopharmaceutical companies, which will be in the upcoming Prohost Letter #430. We believe that the news we are posting will have a positive impact on the firms that announced them. …
Prohost greetings and opinions

Prohost greetings and opinions

We Wish You A Happy Spiritual Season and A Happy New Year 2019. We Hope that Peace of Mind, Serenity  and Optimistic Feelings Replace Unwarranted Pessimistic, False Impressions   That Have No Root in America’s Reality We Love You All Some Common Sense Please If the economy was not solid there would have been no reason for the Federal Reserve to raise interest rates. So, …
What is looking good in the aggressive portfolio

What is looking good in the aggressive portfolio

The Week in Review #29 PROHOST AGGRESSIVE PORTFOLIO  - The aggressive portfolio hosts biotech firms with solid scientific fundamentals and prominent scientists whose stocks have plummeted following some setbacks. A setback could be a failure of an investigational product to meet the endpoints of its clinical trial or that the small biotech firm has taken long to achieve its goals . . . This content …
Reasons for RegenxBio’s outperformance and some other Prohost big winners

Reasons for RegenxBio’s outperformance and some other Prohost big winners

On May 25, in Prohost Letter Issue #421, we wrote about RegenxBio (RGNX), which from behind the scenes it created several gene therapy products that are being used by AveXis, a firm that was recently acquired by Novartis based on its successful pipeline products. In the article (please read it if you missed it and read it again if you forgot it, or were not …
Yesterday’s Prohost Stocks’ Performances: NBIX UP $11.85; JUNO UP $11.60 and EXEL UP $1.35

Yesterday’s Prohost Stocks’ Performances: NBIX UP $11.85; JUNO UP $11.60 and EXEL UP $1.35

EXELIXIS For Exelixis’ excellent news, please read our latest article, "Exelixis’ (EXEL) Exceptional Financial Results and Corporate Achievements", under Today’s Highlights NEUROCRINE BIOSCIENCE Prohost Picked this firm on April 24, 2017, at $51 (see the Prohost Portfolio in the Prohost Letter). Today, Thursday, November 2, NBIX closed on  at $72.78 Up $11.85     In its Q3 report, Neurocrine Biosciences (NBIX) announced financial results that beat …
Prohost Letter #414

Prohost Letter #414

Prohost Letter #414 GIANTS & DWARFS - We believe it’s a useful idea bringing The Week in Review into the Prohost Letter this time. We thought it would be easier for the readers to get last week’s updates and comments together with the Letter’s subjects and its Prohost Portfolio’s observations. In the Week that said au revoir, things happened that are worth citing. New development-stage …
Prohost Letter #407

Prohost Letter #407

Prohost Letter #407 AT A GLANCE - Firms Added to Prohost Portfolio PROHOST IS PICKING NEUROCRINE BIOSCIENCES   On March 27, a few days before the FDA approves Neurocrine’s (NBIX) drug Ingrezza, (valbenazine) capsules for adults with tardive dyskinesia (TD), we posted an article titled “Time for Transformation and Achievements”. In the article, we stated that Neurocrine Sciences Ingrezza will highlight Neurocrine Biosciences and its …
Is Prohost Still Cautious About Investing in Clovis Oncology?

Is Prohost Still Cautious About Investing in Clovis Oncology?

The FDA announced what made Clovis Oncology (CLVS) shareholders believe that the bad times might have ended for the firm and a new era is beginning. The announcement was about the FDA decision not to hold an advisory committee meeting to discuss the company’s New Drug Application (NDA) for drug rucaparib aimed at treating advanced ovarian cancer. The regulatory agency had already granted rucaparib a …
Prohost Letter #394 Part 2

Prohost Letter #394 Part 2

Prohost Letter #394 Part 2 PART 2 - Part 1 of the Prohost letter issue #394 posted on March 31,2016 ended with the review of Ariad Pharmaceuticals (ARIA), one of the biotech firms that have at least one marketed product that we believe have the chance to boost their revenues in the near-future. In this part 2 of the same Prohost Letter, we add other firms …
Prohost Letter #393

Prohost Letter #393

Prohost Letter #393 IMMUNOTHERAPY - PROHOST PORTFOLIO - NEW PICKS? - A Brief Reminder of the CAR T –TCR Immunotherapy Approaches In this issue we continue our journey inside the territory of cancer immunotherapy. We remind that in the Prohost Letter issue #391, we dealt with the immunotherapy based on genetically engineered T Cells, enabling them to seek out, attack and neutralize cancer cells. The immune system’s T …
Prohost Letter #377

Prohost Letter #377

Prohost Letter #377 PICKING BIOTECH FIRMS Before Investing in Them Raising the bar in designating small drug developing firms as biotechnology firms has occurred several times since 2011. In that year, many technologies were tremendously enhanced, which enabled them to realize superior goals, i.e., produce safer and more effective breakthrough drugs for chronic debilitating and life-threatening diseases. Prohost Portfolios picks, which have outperformed other industries’ …
Vertex: Good News and Good Decisions

Vertex: Good News and Good Decisions

Vertex’s Good News Vertex and Kymera Therapeutics Collaboration Last week Vertex Pharmaceuticals (VRTX) and Kymera Therapeutics entered into a four-year strategic research and development collaboration to advance small molecule protein degraders against multiple targets. Kymera is an expert in targeted protein degradation and has its own drug discovery program known as Pegasus™. The collaboration will benefit from this program and from Vertex’s scientific, clinical and regulatory capabilities …
Bluebird bio and Celgene: Encouraging Clinical Trial Results for Last Resort Multiple Myeloma Treatment

Bluebird bio and Celgene: Encouraging Clinical Trial Results for Last Resort Multiple Myeloma Treatment

A Great Day for Bluebird bio and Celgene Read the Clinical Trial Results for Myeloma What a Great Day! Jobs reaching the moon. Inflation not yet showing any concerning signs. A fiercely rebounding stock market. Those who are still listening to pessimistic opinions are missing the fact that technologies and biotechnology are standing at the starting line. They are not yet at the finish line. …
The Week in Review #40

The Week in Review #40

  Conquering NASH Gilead and Novo Nordisk Conquering NASH What was Gilead Sciences' (GILD) announcement at EASL? What is Gilead doing to find effective treatments for NASH? Why would Novo Nordisk's (NVO) anti-diabetes GLP-1 receptor drug fit as part of a combination for NASH treatment? Is there any Proof of concept offered for any of the combination therapies? What percentage of patients had . . . This …
The Amgen/Novartis story. A Little Curiosity About Alder Biopharmaceuticals.

The Amgen/Novartis story. A Little Curiosity About Alder Biopharmaceuticals.

The Amgen/Novartis Story In May 2018 Amgen (AMGN)  & Novartis (NVS) announced that their novel migraine drug Aimovig™ was granted FDA approval for adults. Aimovig is the first and only FDA-approved migraine treatment designed to specifically block calcitonin-gene-related peptide receptor (CGRP-R) believed to play a critical role in causing migraines.  Amgen and Novartis both expressed their excitement for the . . . This content is …
Sangamo’s stock price Soars 52% in pre-market hours on hemophilia A trial results

Sangamo’s stock price Soars 52% in pre-market hours on hemophilia A trial results

Sangamo Therapeutics’ (SGMO) stock soared more than 52% in pre-market trading following the announcement, with Pfizer (PFE), of interim data from Phase 1/2 Alta study evaluating the firm’s gene therapy product SB-525 for severe hemophilia A.  The Product, SB-525 SB-525 comprises a recombinant adeno-associated virus serotype 6 vector (AAV6) encoding the complementary deoxyribonucleic acid for B domain deleted human FVIII. The SB-525 vector cassette was …